Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV

Health CarePharmaceuticals & Biotechnology
  • Price (MXN)23.46
  • Today's Change-0.16 / -0.68%
  • Shares traded2.21m
  • 1 Year change27.50%
  • Beta0.5749
Data delayed at least 20 minutes, as of Aug 03 2020 20:59 BST.
More ▼

Profile data is unavailable for this security.

About the company

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

  • Revenue in MXN (TTM)12.91bn
  • Net income in MXN885.84m
  • Incorporated1996
  • Employees1.29k
  • Location
    Genomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeMEXICO, D.F. 01210MexicoMEX
  • Phone+52 5 550810000
  • Fax+52 5 550810000
  • Websitehttp://www.genommalab.com/mx/
More ▼

Institutional shareholders

23.93%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 May 202050.55m4.82%
Massachusetts Financial Services Co.as of 31 May 202046.63m4.45%
Capital Research & Management Co. (World Investors)as of 30 Jun 202035.95m3.43%
The Vanguard Group, Inc.as of 30 Jun 202024.88m2.37%
Invesco Advisers, Inc.as of 31 Mar 202022.64m2.16%
BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 09 Jul 202019.86m1.90%
Dimensional Fund Advisors LPas of 30 Apr 202016.65m1.59%
BlackRock Fund Advisorsas of 09 Jul 202012.44m1.19%
Norges Bank Investment Managementas of 31 Dec 201912.39m1.18%
AllianceBernstein LPas of 31 May 20208.77m0.84%
More ▼
Data from 31 Dec 2019 - 29 Jul 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.